VYTRUS BIOTECH EO -01 Market Cap ($125.66 Million)
Market Cap & Net Worth: VYTRUS BIOTECH EO -01 (V5P)
VYTRUS BIOTECH EO -01 market cap. VYTRUS BIOTECH EO -01 (F:V5P) has a market capitalization of $125.66 Million (€107.49 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #18161 globally and #1696 in its home market, demonstrating a -4.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VYTRUS BIOTECH EO -01's stock price €14.30 by its total outstanding shares 7516458 (7.52 Million). Also see V5P cash generation efficiency for how efficiently the company converts equity into cash flow.
VYTRUS BIOTECH EO -01 Market Cap History (2022–2026)
VYTRUS BIOTECH EO -01 market cap history from 2022 to 2026. Data shows growth from $29.44 Million to $125.66 Million (35.38% CAGR). Check VYTRUS BIOTECH EO -01 (V5P) share price today for real-time trading data and today's change.
VYTRUS BIOTECH EO -01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VYTRUS BIOTECH EO -01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is VYTRUS BIOTECH EO -01 growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
11.02x
VYTRUS BIOTECH EO -01's market cap is 11.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
31.85x
VYTRUS BIOTECH EO -01's market cap is 31.85 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $29.44 Million | $3.68 Million | $605.26K | 7.99x | 48.64x |
| 2023 | $24.61 Million | $3.74 Million | $544.94K | 6.58x | 45.15x |
| 2024 | $18.98 Million | $5.04 Million | $1.02 Million | 3.76x | 18.59x |
| 2025 | $92.27 Million | $8.37 Million | $2.90 Million | 11.02x | 31.85x |
Competitor Companies of V5P by Market Capitalization
Companies near VYTRUS BIOTECH EO -01 in the global market cap rankings as of November 4, 2026. Also see V5P asset base for a full breakdown of the balance sheet.
Key companies related to VYTRUS BIOTECH EO -01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of VYTRUS BIOTECH EO -01 (2022–2026)
Market capitalization of VYTRUS BIOTECH EO -01 from 2022 to today. Between 2022 and today, VYTRUS BIOTECH EO -01's market cap moved from $29.44 Million to $ 125.66 Million, with a yearly change of 35.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €125.66 Million | +36.19% |
| 2025 | €92.27 Million | +386.11% |
| 2024 | €18.98 Million | -22.86% |
| 2023 | €24.61 Million | -16.42% |
| 2022 | €29.44 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of VYTRUS BIOTECH EO -01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $125.66 Million USD |
| MoneyControl | $125.66 Million USD |
| MarketWatch | $125.66 Million USD |
| marketcap.company | $125.66 Million USD |
| Reuters | $125.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more